Paper36977782
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.
Ussher JR and 1 other. Nat Rev Cardiol, 2023. Cited by 479 papers, by iCite.
Cite this record
ConductScience Library. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Papers, record 36977782. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36977782
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Cardiovascular System | Major topic |
| Cardiovascular Diseases | Major topic |
| Humans | |
| Hypoglycemic Agents | |
| Glucagon-Like Peptide 1 | |
| Obesity | |
| Glucagon-Like Peptide-1 Receptor Agonists |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06877572 | Weight Loss Management in Endometrial Cancer Survivors | Background |
Source ClinicalTrials.gov
References126
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36545339 | Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis. | Front Endocrinol (Lausanne) | 2022 | https://conductscience.org/library/papers/36545339 | PubMed |
| 2 | 35907261 | Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease. | Endocr Rev | 2023 | https://conductscience.org/library/papers/35907261 | PubMed |
| 3 | 36027914 | Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation. | Cell Metab | 2022 | https://conductscience.org/library/papers/36027914 | PubMed |
| 4 | 17098089 | The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. | Lancet | 2006 | https://conductscience.org/library/papers/17098089 | PubMed |
| 5 | 28249135 | Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28249135 | PubMed |
| 6 | 29091756 | Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion. | Cell Rep | 2017 | https://conductscience.org/library/papers/29091756 | PubMed |
| 7 | 29217412 | Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins. | J Clin Lipidol | 2018 | https://conductscience.org/library/papers/29217412 | PubMed |
| 8 | 26432951 | Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. | J Mol Cell Cardiol | 2015 | https://conductscience.org/library/papers/26432951 | PubMed |
| 9 | 33983836 | Cardiac Energy Metabolism in Heart Failure. | Circ Res | 2021 | https://conductscience.org/library/papers/33983836 | PubMed |
| 10 | 30384842 | Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial. | Cardiovasc Diabetol | 2018 | https://conductscience.org/library/papers/30384842 | PubMed |
| 11 | 29444223 | GLP-1 Receptor Expression Within the Human Heart. | Endocrinology | 2018 | https://conductscience.org/library/papers/29444223 | PubMed |
| 12 | 35958685 | Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation. | JACC Basic Transl Sci | 2022 | https://conductscience.org/library/papers/35958685 | PubMed |
| 13 | 33320179 | Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. | Endocr Rev | 2021 | https://conductscience.org/library/papers/33320179 | PubMed |
| 14 | 25414155 | Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. | Diabetes Care | 2015 | https://conductscience.org/library/papers/25414155 | PubMed |
| 15 | 23868944 | Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. | Arterioscler Thromb Vasc Biol | 2013 | https://conductscience.org/library/papers/23868944 | PubMed |
| 16 | 33446799 | Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better. | Sci Rep | 2021 | https://conductscience.org/library/papers/33446799 | PubMed |
| 17 | 19627582 | Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. | BMC Cardiovasc Disord | 2009 | https://conductscience.org/library/papers/19627582 | PubMed |
| 18 | 25735732 | GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R. | Diabetes | 2015 | https://conductscience.org/library/papers/25735732 | PubMed |
| 19 | 19195607 | Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. | J Am Coll Cardiol | 2009 | https://conductscience.org/library/papers/19195607 | PubMed |
| 20 | 24296712 | Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. | Diabetes | 2014 | https://conductscience.org/library/papers/24296712 | PubMed |
Cited by298
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 479 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42979257 | Type 2 diabetes and the cardio-renal-metabolic syndrome: The evolving roles of GLP-1 and dual GLP-1/GIP receptor agonists. | touchREV Endocrinol | 2026 | https://conductscience.org/library/papers/42979257 | PubMed |
| 42947001 | Comparison of cardiac adverse event signal profiles for GLP-1 receptor agonists: an analysis of the FAERS database. | BMC Cardiovasc Disord | 2026 | https://conductscience.org/library/papers/42947001 | PubMed |
| 42941702 | GLP-1-Based Therapies for Cardiovascular Risk Reduction in Kazakhstan: Evidence, Affordability, Equity and Implementation Considerations. | J Clin Med | 2026 | https://conductscience.org/library/papers/42941702 | PubMed |
| 42936196 | Real-world effectiveness of liraglutide in children with type 2 diabetes. | J Endocr Soc | 2026 | https://conductscience.org/library/papers/42936196 | PubMed |
| 42878985 | GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases. | Curr Atheroscler Rep | 2026 | https://conductscience.org/library/papers/42878985 | PubMed |
| 42865473 | GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and meta-analysis of randomized controlled trials. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42865473 | PubMed |
| 42857051 | Baseline BMI and weight change in dilated cardiomyopathy: associations with LVEF, BNP, and NYHA class. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42857051 | PubMed |
| 42851902 | Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42851902 | PubMed |
| 42812847 | Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study. | J Endocr Soc | 2026 | https://conductscience.org/library/papers/42812847 | PubMed |
| 42775225 | Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42775225 | PubMed |
| 42746268 | Real-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data. | Mayo Clin Proc Digit Health | 2026 | https://conductscience.org/library/papers/42746268 | PubMed |
| 42713454 | Glucagon-Like Peptide-1 Receptor Agonist Use Before and After Liver Transplant. | Gastroenterol Hepatol (N Y) | 2026 | https://conductscience.org/library/papers/42713454 | PubMed |
| 42709280 | Effects of heart failure pharmacotherapy on natriuresis and diuresis: A narrative review. | Heart Fail Rev | 2026 | https://conductscience.org/library/papers/42709280 | PubMed |
| 42669711 | Cardiovascular outcome of glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitor on end-stage kidney disease patients with heart failure: an emulated target trial in patients with diabetes. | Nat Commun | 2026 | https://conductscience.org/library/papers/42669711 | PubMed |
| 42642762 | Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study. | Cardiovasc Diabetol | 2026 | https://conductscience.org/library/papers/42642762 | PubMed |
| 42642357 | Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation. | Diabetes Obes Metab | 2026 | https://conductscience.org/library/papers/42642357 | PubMed |
| 42630726 | Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy. | Front Urol | 2026 | https://conductscience.org/library/papers/42630726 | PubMed |
| 42629417 | Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs). | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/42629417 | PubMed |
| 42612051 | Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis. | J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/42612051 | PubMed |
| 42598740 | Reply. | Arthritis Rheumatol | 2026 | https://conductscience.org/library/papers/42598740 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36977782
GET https://conductscience.org/api/papers/v1/36977782/references?page=2